• 정보보호학회논문지
• /
• 제13권6호
• /
• pp.77-84
• /
• 2003

이동 에이전트는 네트워크에서 사용자를 대신하여 특정 작업을 수행하면서, 자율적으로 한 노드에서 다른 노드로 이주할 수 있는 프로그램이다. 본 연구에서는 이동 에이전트가 여러 노드들을 이주하면서 실행하다가 비정상적인 종료 상황이 발생했을 때 이전 사이트에 저장한 이동 에이전트의 체크포인트를 이용해서 이동 에이전트를 안전하게 복원하고 실행을 재개할 수 있는 기법을 제안한다. 체크포인트의 보안을 위해 이동 에이전트의 공개키를 이용하여 체크 포인트를 암호화하여 저장하고, 복원 시에는 홈 플랫폼에서 이동 에이전트의 비밀키를 이용해서 이동 에이전트를 복원한다. 홈 플랫폼이 이동 에이전트를 복원하기 위해서 체크포인트를 수신하였을 때 이 체크포인트가 올바른 체크포인트인지 확인하기 위해서 메시지 다이제스트를 이용하며, 이동 에이전트가 체크포인트를 만들 때 생성한 메시지 다이제스트와 복원 시에 만든 메시지 다이제스트를 비교함으로써 홈 플랫폼은 수신한 이동 에이전트의 체크포인트의 정확성을 확인할 수 있게 된다.

• 미생물학회지
• /
• 제37권1호
• /
• pp.28-36
• /
• 2001

본 연구에서는 세포주기의 Gl/S기에 관련된 유전자의 작용기작을 이해하기 위하여 출아효모인 Saccharomyces cerevisiae를 사용하여 세포주기 진행 및 조절에 관련된 변이주를 분 리하여 특성화하는 연구를 수행하였다. 먼저 새로운 변이주를 분리하기 위해서 HeLa 세포와 출아효모에서 Gl을 유발하는 CPO(ciclopirox olamine) 약제에 대해 감수성을 보이는 변이주를 선별하였다. 그 결과, 총 31개의 CPO에 대한 감수성 변이주들이 분리되었고, ciclopirox olamine sensitivity의 첫 글자를 따서 con mutants라 명명하였다. cos 변이주들의 표현형의 특성을 결정하기 위해 MMS(methylmethane sulfonate)와 HU(hydrsxyurea)에 대한 감수성을 조사하여 그 성질에 따라 4개의 group으로 나누었다. Group I에는 cos27, cos28, cos32, cos33, cos36, cos37, cos40, cos42, cos46, cos50, cos52, cos53 변이주가 포함되고, 이들은 MMS와 HU 두 약제 모두에 대해서 감수성을 보여 S기 checkpoint에 관련된 것으로 보이고, Group II는 cos43, cos48 변이주로 MMS에 대해서 감수성을 지녀 G1기 또는 G2기 checkpoint에 관련된 것으로 추측된다. Group III 변이주에는 cos35, cos47, cos54, cos55, cos56이 포함되고 HU에 대해서 감수성을 보여 S기에 관련된다고 보여지며, Group IV 변이 주는 cos29, cos30, cos31, cos34, cos38, cos39, cos41, cos44, cos45, cos49, cos51, cos57로서 단지 CPO에 대해서만 감수성을 나타냈다. 더욱이 변이주의 최종표현형을 형광현미경을 이용하여 조사하여, S기 checkpoint에 관련된 것으로 보이는 cos37 변이주를 확인하였다. 또한, 변이주와 야생주의 이형접합체인 이배체를 만들어 변이주의 유전학적 분석을 수행하였다.

• Journal of Gastric Cancer
• /
• 제23권3호
• /
• pp.476-486
• /
• 2023

Purpose: The optimal tumor mutational burden (TMB) value for predicting treatment response to programmed cell death-1 (PD-1) checkpoint inhibitors in advanced gastric cancer (AGC) remains unclear. We aimed to investigate the optimal TMB cutoff value that could predict the efficacy of PD-1 checkpoint inhibitors in AGC. Materials and Methods: Patients with AGC who received pembrolizumab or nivolumab between October 1, 2020, and July 27, 2021, at Samsung Medical Center in Korea were retrospectively analyzed. The TMB levels were measured using a next-generation sequencing assay. Based on receiver operating characteristic curve analysis, the TMB cutoff value was determined. Results: A total 53 patients were analyzed. The TMB cutoff value for predicting the overall response rate (ORR) to PD-1 checkpoint inhibitors was defined as 13.31 mutations per megabase (mt/Mb) with 56% sensitivity and 95% specificity. Based on this definition, 7 (13.2%) patients were TMB-high (TMB-H). The ORR differed between the TMB-low (TMB-L) and TMB-H (8.7% vs. 71.4%, P=0.001). The progression-free survival and overall survival (OS) for 53 patients were 1.93 (95% confidence interval [CI], 1.600-2.268) and 4.26 months (95% CI, 2.992-5.532). The median OS was longer in the TMB-H (20.8 months; 95% CI, 2.292-39.281) than in the TMB-L (3.31 months; 95% CI, 1.604-5.019; P=0.049). Conclusions: The TMB cutoff value for predicting treatment response in AGC patients who received PD-1 checkpoint inhibitor monotherapy as salvage treatment was 13.31 mt/Mb. When applying the programmed death ligand-1 status to TMB-H, patients who would benefit from PD-1 checkpoint inhibitors can be selected.

• Journal of Information Technology Applications and Management
• /
• 제11권2호
• /
• pp.29-43
• /
• 2004

As the development of an information technique, gradually, mobile device is going to be miniaturized and operates at high speed. By such the requirements, the devices using a flash memory as a storage media are increasing. The flash memory consumes low power, is a small size, and has a fast access time like the main memory. But the flash memory must erase for recording and the erase cycle is limited. JFFS is a representative filesystem which reflects the characteristics of the flash memory. JFFS to be consisted of LSF structure, writes new data to the flash memory in sequential, which is not related to a file size. Mounting a filesystem or an error recovery is achieved through the sequential approach. Therefore, the mounting delay time is happened according to the file system size. This paper proposes a MJFFS to use a multi-checkpoint information to manage a mass flash file system efficiently. A MJFFS, which improves JFFS, divides a flash memory into the block for suitable to the block device, and stores file information of a checkpoint structure at fixed interval. Therefore mounting and error recovery processing reduce efficiently a number of filesystem access by collecting a smaller checkpoint information than capacity of actual files. A MJFFS will be suitable to a mobile device owing to accomplish fast mounting and error recovery using advantage of log foundation filesystem and overcoming defect of JFFS.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2005년도 춘계학술대회
• /
• pp.5-14
• /
• 2005

Recently, data from several groups have raised the concept of 'checkpoint' in transcription. As capping of nascent RNA transcript is tightly coupled to RNA polymerase II transcription, we seek to obtain direct evidence that transcripiton checkpoint via capping enzyme functions in this early regulatory step. One of temperature sensitive (ts) alleles of ceg1, a guanylyltransferase subunit of the Saccharomyces cerevisiaecapping enzyme, showed 6-azauracil (6AU) sensitivity at the permissive growth temperature, which is a phenotype that is correlated with a transcription elongational defect. This ts allele, ceg1-63 also has an impaired ability to induce PUR5 in response to a 6AU treatment. However, this cellular and molecular defect is not due to the preferential degradation of the transcript attributed from a lack of guanylyltransferase activity. On the contrary, the data suggests that the guanylyltransferase subunit of the capping enzyme plays a role in transcription elongation. First, in addition to the 6AU sensitivity, ceg1-63is synthetically lethal with elongation defective mutations of the largest subunit of RNA polymerase II. Secondly, it exhibited a lower GAL1 mRNA turn-over after glucoseshut off. Third, it decreased the transcription read through a tandem array of promoter proximal pause sites in an orientation dependent manner. Interestingly, this mutant also showed lower pass through a pause site located further downstream of the promoter. Taken together, these results suggest that the capping enzyme plays the role of an early transcription checkpoint possibly in the step of the reversion of repression by stimulating polymerase to escape from the promoter proximal arrest once RNA becomes appropriately capped.

• BMB Reports
• /
• 제47권5호
• /
• pp.249-255
• /
• 2014

Polo-like kinase-1 (Plk1) belongs to a family of serine-threonine kinases and plays a critical role in mitotic progression. Plk1 involves in the initiation of mitosis, centrosome maturation, bipolar spindle formation, and cytokinesis, well-reported as traditional functions of Plk1. In this review, we discuss the role of Plk1 during DNA damage response beyond the functions in mitotsis. When DNA is damaged in cells under various stress conditions, the checkpoint mechanism is activated to allow cells to have enough time for repair. When damage is repaired, cells progress continuously their division, which is called checkpoint recovery. If damage is too severe to repair, cells undergo apoptotic pathway. If damage is not completely repaired, cells undergo a process called checkpoint adaptation, and resume cell division cycle with damaged DNA. Plk1 targets and regulates many key factors in the process of damage response, and we deal with these subjects in this review.

• 정보처리학회논문지A
• /
• 제11A권5호
• /
• pp.313-318
• /
• 2004

본 논문에서는 장시간 실행이 예상되는 결함 허용 프로세스를 위한 검사점 및 복구 도구를 제시한다. 제시한 도구의 기본 개념은 프로세스의 실행 상태를 주기적으로 저장함으로써 시스템 결항으로 인해 실행이 정지되었을 경우, 결함이 발생하기 전의 실행 상태를 복구하여 계속 실행시키는 것이다. 제시한 도구에서는 검사점 및 복구를 위하여 결함 허용 프로세스의 소스 코드를 수정할 필요가 없다. 이를 위하여 결함 허용 프로세스를 위한 파일명과 검사점 주기를 사용자가 직접 지정하도록 설계하고, 두 개의 시스템 호출(Save, recover)을 추가하였다. 마지막으로 제시한 기법의 타당성을 검토하기 위하여 리눅스 환경(커널 2.4.18)에서 구현하였다.

• 한국정보처리학회:학술대회논문집
• /
• 한국정보처리학회 2013년도 춘계학술발표대회
• /
• pp.476-477
• /
• 2013

Gadget-2 is a scientific simulation code has been used for many different types of simulations like, Colliding Galaxies, Cluster Formation and the popular Millennium Simulation. The code is parallelized with Message Passing Interface (MPI) and is written in C language. There is also a Java adaptation of the original code written using MPJ Express called Java Gadget. Java Gadget writes a lot of checkpoint data which may or may not use the HDF-5 file format. Since, HDF-5 is MPI-IO compliant, we can use our MPJ-IO library to perform parallel reading and writing of the checkpoint files and improve I/O performance. Additionally, to add reliability to the code execution, we propose the usage of Hadoop Distributed File System (HDFS) for writing the intermediate (checkpoint files) and final data (output files). The current code writes and reads the input, output and checkpoint files sequentially which can easily become bottleneck for large scale simulations. In this paper, we propose Sim-Hadoop, a framework to leverage HDFS and MPJ-IO for improving the I/O performance of Java Gadget code.

• Journal of Digestive Cancer Research
• /
• 제10권1호
• /
• pp.22-30
• /
• 2022

Immune checkpoint inhibition has been established as a new treatment option for various types of carcinoma, and many clinical trials are being actively conducted as a treatment for advanced or metastatic gastric cancer, either as a monotherapy with an immune checkpoint inhibitor or as a combination therapy with standard chemotherapy. In the CheckMate-649 clinical trial to confirm the efficacy of the combination of nivolumab and chemotherapy (FP) in advanced gastric cancer and gastroesophageal junction cancer, nivolumab group showed improvement in overall survival in programmed death ligand 1-positive cancer patients compared with placebo group. Also, the combination therapy of pembrolizumab, trastuzumab and chemotherapy (FP) in first-line treatment was tested through the KEYNOTE-811 trial. The pembrolizumab group showed 22.7% of improvement in objective response rate compared with placebo group. Accordingly, the combination of nivolumab/pembrolizumab with standard chemotherapy was approved for the first-line treatment. In KEYNOTE-059 trials for patients with progressive disease after at least two lines of chemotherapy, pembrolizumab monotherapy showed improvement in objective response rate and overall survival, and the use of pembrolizumab was approved for the third-line or more treatment. In this article, we review the result of clinical trials related to immune checkpoint inhibitors that have been recently introduced in the treatment of gastric cancer.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.2.1-2.22
• /
• 2022

Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved in 2011 for treatment of metastatic melanoma, eight immune checkpoint inhibitors (ICIs) centered on PD-1 pathway blockade are approved and currently administered to treat 18 different types of cancers. The first part of the review focuses on the history of CTLA-4 and PD-1 discovery and the preclinical experiments that demonstrated the possibility of anti-CTLA-4 and anti-PD-1 as anti-cancer therapeutics. The approval process of clinical trials and clinical utility of ICIs are described, specifically focusing on non-small cell lung cancer (NSCLC), in which immunotherapies are most actively applied. Additionally, this review covers the combination therapy and novel ICIs currently under investigation in NSCLC. Although ICIs are now key pivotal cancer therapy option in clinical settings, they show inconsistent therapeutic efficacy and limited responsiveness. Thus, newly proposed action mechanism to overcome the limitations of ICIs in a near future are also discussed.